Skip to content
Screener

Replimune Group REPL Business Segments — Other Income (Expense)

Similar metrics at other companies

PayPal Holdings, Inc. logo
PYPLReportable Segment — Other Income (Expense)
-$117M-568%
Twist Bioscience Corporation logo
TWSTReportable Segment — Other Income (Expense)
$175K+144%
Lucid Group, Inc. logo
LCIDReportable Segment — Other Income (Expense)
-$7.87M-365%
Arcutis Biotherapeutics, Inc. logo
ARQTReportable Segment — Other Income (Expense)
-$157K-885%
DoorDash logo
DASHReportable Segment — Other Income (Expense)
$16M-72.9%
Inseego Corp. logo
INSGReportable Segment — Other Income (Expense)
$43K-76.4%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$1.01B+195%
Enterprise value$967.91M+199%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: Replimune Group’s 10-Q, filed February 3, 2026.

Filed
Feb 3, 2026, 8:12 AM EST
Fiscal quarter
Q3 FY2026
Calendar quarter
Q4 2025
Accession
0001628280-26-004805
Operating expenses:Three Months Ended December 31, 2025 / (Amounts in thousands)Three Months Ended December 31, 2024 / (Amounts in thousands)Nine Months Ended December 31, 2025 / (Amounts in thousands)Nine Months Ended December 31, 2024 / (Amounts in thousands)
Unallocated research and development expenses¹:30,43231,572102,40189,695
Selling, general and administrative18,72818,01577,72146,827
Total operating expenses71,86866,019246,581182,299
Loss from operations(71,868)(66,019)(246,581)(182,299)
Other income (expense), net627$254$5,547$9,707
Loss before income taxes$(71,241)$(65,765)$(241,034)$(172,592)
Income tax (benefit) provision(311)575(311)575
Net loss(70,930)(66,340)(240,723)(173,167)

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Replimune Group's business segments — other income (expense)?
Replimune Group (REPL) reported business segments — other income (expense) of $627K in Q4 2025.
How has Replimune Group's business segments — other income (expense) changed year-over-year?
Replimune Group's business segments — other income (expense) increased by 146.9% year-over-year, from $254K to $627K.
What does business segments — other income (expense) mean?
Includes non-operating financial items such as interest income from cash balances, interest expense on debt, and foreign currency exchange gains or losses. This metric reflects the impact of the company's treasury management and capital structure on the bottom line, independent of core clinical operations.

Ask your AI about Replimune Group's business segments — other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude